Format

Send to

Choose Destination
Toxicol In Vitro. 2019 Dec;61:104613. doi: 10.1016/j.tiv.2019.104613. Epub 2019 Jul 29.

Effect of bergenin on RANKL-induced osteoclast differentiation in the presence of methylglyoxal.

Author information

1
Department of Endocrinology & Metabolism, School of Medicine, Kyung Hee University, 1, Hoegi-dong, Dongdaemun-gu, Seoul 02447, Republic of Korea.
2
Department of Biomedical Laboratory Science, College of Health Sciences, Cheongju University, Cheongju, Chungbuk 28503, Republic of Korea.
3
Department of Endocrinology & Metabolism, School of Medicine, Kyung Hee University, 1, Hoegi-dong, Dongdaemun-gu, Seoul 02447, Republic of Korea. Electronic address: cheunmi@hanmail.net.

Abstract

Methylglyoxal (MG), a highly reactive dicarbonyl compound, is a major precursor in the formation of advanced glycation end products, which are associated with diabetes-related diseases. Bergenin, an active constituent of plants of the genus Bergenia, exhibits multiple biological activities. This study evaluated the effect of bergenin on osteoclast differentiation and determined its mechanism of action. Bergenin reversed MG-inhibited tartrate-resistant acid phosphatase (TRAP) activity and decreased the bone resorption activity of osteoclasts. Quantitative RT-PCR revealed that bergenin decreased the expression of ERK1, Akt2, MMP-9, and OSTM1 genes in the presence of MG. Bergenin pretreatment yielded significant increases in intracellular calcium concentration, mitochondrial mass, mitochondrial membrane potential, and glyoxalase I reduced by MG. Additionally, bergenin decreased the formation of mitochondrial superoxide induced by MG. Detoxification of MG by bergenin may be a viable treatment for bone disorders in patients with diabetes.

KEYWORDS:

Bergenin; Differentiation; Methylglyoxal; Osteoclast

PMID:
31369791
DOI:
10.1016/j.tiv.2019.104613
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center